Immunotherapy in hepatocellular carcinoma: How does underlying liver disease influence therapeutic strategy and outcomes?-Reference-Cited by-同舟云学术

Immunotherapy in hepatocellular carcinoma: How does underlying liver disease influence therapeutic strategy and outcomes?

Published:2023-01-06 Issue:3 Volume:43 Page:546-557
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver International

Author:

Roth Gael S.¹^ORCID,Villeret François²³^ORCID,Decaens Thomas¹^ORCID,Merle Philippe²³,Nahon Pierre⁴⁵^ORCID

Affiliation:

1. Université Grenoble Alpes, Hepato‐Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes, Institute for Advanced Biosciences, CNRS UMR 5309‐INSERM U1209 Grenoble France

2. Hepatology Department, Hepatology Institute of Lyon Croix‐Rousse Hospital, University Hospital of Lyon Lyon France

3. Cancer Research Centre of Lyon (CRCL), INSERM U1052, CNRS UMR 5286 University Claude Bernard Lyon 1 Lyon France

4. Liver Unit Avicenne Hospital, AP‐HP Bobigny France

5. Functional Genomics of Solid Tumours, Cordelier Research Center, INSERM UMR‐1138 Sorbonne University Paris France

Funder

Ipsen

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15504

Reference53 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

3. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

4. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?;Cancer Treatment Reviews;2024-09

2. Atezolizumab and bevacizumab with anticoagulant or antiplatelet therapy in hepatocellular carcinoma patients: Real‐world data for informed clinical decision‐making;Liver International;2024-07-16

3. Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?;Digestive and Liver Disease;2023-09

4. A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective study;PeerJ;2023-08-24

5. Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma;Cancers;2023-07-15